Search Result

Results for "

LTB4 receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Calcium Channel (1) CCR (1) Drug Metabolite (1) Endogenous Metabolite (4) Histamine Receptor (1) Leukotriene Receptor (21) Lipoxygenase (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Inflammation/Immunology (22) Metabolic Disease (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112741

SB-209247	Leukotriene Receptor	Inflammation/Immunology
SB-209247 is a selective, high affinity and orally active leukotriene B4 (LTB4) receptor antagonist with a K_i of 0.78 nM. SB-209247 blocks LTB4-induced Ca ²⁺ mobilization with an IC₅₀ of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity .

HY-112737

LY223982 CGS23131; SKF107324	Leukotriene Receptor	Inflammation/Immunology
LY223982 is a potent and specific inhibitor of leukotriene B4 receptor, with an IC₅₀ of 13.2 nM against [ ³H]LTB4 binding to LTB4 receptor.

HY-114641A

BIIL-260 hydrochloride	Leukotriene Receptor	Inflammation/Immunology
BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor *LTB₄* antagonist, with anti-inflammatory activity. BIIL-260 hydrochloride interacts with the LTB₄ receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB₄ receptor on isolated human neutrophil cell membranes with K_i values of 1.7 nM .

HY-15744

LY255283 3 Publications Verification	Leukotriene Receptor	Inflammation/Immunology Cancer
LY255283 is a LTB₄ receptor (BLT2) antagonist, with an IC₅₀ of ~100 nM for [ ³H]LTB₄ binding to guinea pig lung membranes .

HY-122536

Ricinelaidic acid	Leukotriene Receptor Calcium Channel Endogenous Metabolite	Inflammation/Immunology
Ricinelaidic acid, a 12-hydroxy fatty acid，is a leukotriene B4 (LTB4) receptor antagonist with the K_i of 2 μM in porcine neutrophil membranes. Ricinelaidic acid inhibits chemotaxis and calcium flux induced by LTB4 in isolated human neutrophils (IC₅₀=10 and 7 μM, respectively). Ricinelaidic acid inhibits bronchoconstriction induced by LTB4 in rats .

HY-115390

14,15-Dehydro Leukotriene B4	Leukotriene Receptor	Cardiovascular Disease Inflammation/Immunology
14,15-Dehydro Leukotriene B4 (Compound 4) is a **LTB4 receptor antagonist. 14,15-Dehydro Leukotriene B4 also has a higher binding affinity for BLT1 with a K_i value of 27 nM and BLT2 with a K_i** value of 473 nM. 14,15-Dehydro Leukotriene B4 inhibits LTB4-induced release of lysozymes from rat polymorphonuclear leukoctyes with an IC₅₀ value of 1 µM .

HY-149083

LTB4 antagonist 2	Leukotriene Receptor	Inflammation/Immunology
LTB4 antagonist 2, a carboxamide-acid compound, is an antagonist of leukotriene B4 (LTB4) with potentially anti-inflammatory activity. LTB4 antagonist 2 shows good affinity for the **LTB4 receptor with IC₅₀** of 439 nM .

HY-117896

SC-50605	Leukotriene Receptor	Inflammation/Immunology
SC-50605 and SC-51146 are second-generation leukotriene B4 (LTB4) receptor antagonists that effectively inhibit LTB4-induced chemotaxis in guinea pigs. SC-50605 targets the LTB4 receptor and has the potential to inhibit inflammatory diseases such as asthma, rheumatoid arthritis, and skin diseases. .

HY-114641

BIIL-260	Leukotriene Receptor	Inflammation/Immunology
BIIL-260 is a potent and long-acting orally active leukotriene B(4) receptor *LTB₄* antagonist, with anti-inflammatory activity. BIIL-260 interacts with the LTB₄ receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB₄ receptor on isolated human neutrophil cell membranes with the K_i value of 1.7 nM .

HY-100173

DW-1350	Leukotriene Receptor	Inflammation/Immunology
DW-1350 is a **LTB₄ receptor** antagonist.

HY-113483

20-Carboxy-Leukotriene B4 20-COOH LTB4	Drug Metabolite Leukotriene Receptor	Metabolic Disease
20-Carboxy-Leukotriene B4 (20-COOH LTB4) is a metabolite of Leukotriene B4 (LTB4; HY-107608). 20-Carboxy-Leukotriene B4 binds to the BLT1 receptor with high affinity. 20-Carboxy-Leukotriene B4 inhibits LTB4-mediated neutrophil responses (migration, degranulation, leukotriene biosynthesis) .

HY-13628A

Etalocib sodium LY293111 sodium; VML 295 sodium	Leukotriene Receptor Apoptosis	Inflammation/Immunology Cancer
Etalocib (LY293111) sodium, an orally active leukotriene B₄ receptor antagonist, inhibits the binding of [ ³H]LTB₄, with a K_i of 25 nM. Etalocib sodium prevents LTB₄-induced calcium mobilization with an lC₅₀ of 20 nM. Etalocib sodium induces apoptosis .

HY-19304

Amelubant BIIL 284	Leukotriene Receptor	Inflammation/Immunology
Amelubant (BIIL 284) is a potent, oral and long acting **LTB₄ receptor** antagonist, negligibly binds to LTB₄ receptor, with K_is of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a proagent of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity .

HY-131651

Leukotriene B4 ethanolamide LTB4 ethanolamide	Endogenous Metabolite Leukotriene Receptor	Cancer
Leukotriene B4 ethanolamide (LTB4 ethanolamide) is an antagonist and a partial agonist for Leukotriene B4 (LTB4) receptor 1 (BLTR1). Leukotriene B4 ethanolamide ameliorates the tumor progression, which is only asscociated with inflammation .

HY-13628

Etalocib 2 Publications Verification LY293111; VML 295	Leukotriene Receptor Apoptosis	Inflammation/Immunology Cancer
Etalocib (LY293111), an orally active leukotriene B₄ receptor antagonist, inhibits the binding of [ ³H]LTB₄, with a K_i of 25 nM. Etalocib (LY293111) prevents LTB₄-induced calcium mobilization with an lC₅₀ of 20 nM. Etalocib (LY293111) induces apoptosis .

HY-U00263

LY210073	Leukotriene Receptor	Inflammation/Immunology
LY210073 is a Leukotriene B₄ (LTB₄) receptor antagonist with an IC₅₀ of 6.2 nM.

HY-121621

RO5101576	Endogenous Metabolite	Inflammation/Immunology
RO5101576 is a potent LTB4 receptor antagonist with activity to inhibit LTB4-induced calcium mobilization and chemotaxis of human neutrophils. RO5101576 significantly attenuated LTB4-induced pulmonary eosinophilia in guinea pigs. RO5101576 inhibited allergen- and ozone-induced pulmonary neutrophilia in nonhuman primates with efficacy comparable to that of budesonide. RO5101576 had no effect on LPS-induced neutrophilia in guinea pigs and cigarette smoke-induced neutrophilia in mice and rats. RO5101576 performed well in toxicology studies and was well tolerated .

HY-112742

CP-195543	Leukotriene Receptor	Inflammation/Immunology
CP-195543 is a potent, selective and orally active leukotriene B4 (LTB4) receptor antagonist with IC₅₀s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration .

HY-117557

LY306669	Leukotriene Receptor	Inflammation/Immunology
LY306669 is a potent and selective leukotriene B4 (LTB4) receptor antagonist that can be used for the research of lung injury .

HY-108396

γ-Linolenic acid ethyl ester Ethyl γ-linolenate	Leukotriene Receptor	Inflammation/Immunology
γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B₄ receptor 4 (LTB₄) antagonist .

HY-117706

LY 292728	Leukotriene Receptor	Inflammation/Immunology
LY 292728 is a potent leukotriene B4 (LTB4) receptor antagonist. LY 292728 binds to human neutrophils with a K_i of 0.47 nM and binds to guinea pig lung membranes with a K_i of 0.04 nM .

HY-117854

SB 201146	Leukotriene Receptor	Inflammation/Immunology
SB 201146 is an *LTB4* receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma .

HY-19443

UCB-35440	Histamine Receptor Lipoxygenase	Inflammation/Immunology
UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 inhibits LTB4 formation in human whole blood and reduces polymorphonuclear cell infiltration in mouse models. UCB-35440 inhibits histamine-stimulated bronchoconstriction and reduces skin inflammation in guinea pigs. UCB-35440 can be used for research on asthma and skin inflammation .

HY-103360

J-113863 3 Publications Verification	CCR	Inflammation/Immunology
J-113863 is a potent and selective CCR1 antagonist with IC₅₀ values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively. J-113863 is also a potent antagonist of the human CCR3 (IC₅₀ of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC₅₀ of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect .

HY-141635

cis-11,14-Eicosadienoic acid methyl ester	Endogenous Metabolite	Metabolic Disease
cis-11,14-Eicosadienoic acid methyl ester is a more lipid soluble form of the ω-6 C20-2 fatty acid 11(Z),14(Z)-eicosadienoic acid, a naturally occurring PUFA. 11(Z),14(Z)-Eicosadienoic acid competitively inhibits inosine 5’-monophosphate dehydrogenase (Ki=3.1 μM) and inhibits the binding of LTB4 to its receptor on neutrophils (Ki=3.0 μM). Also, serum levels of eicosadienoic acids negatively correlate with degree of sleep disturbance.3 Eicosadienoic acids are converted by desaturases, in vivo, to eicosatrienoic acids, which are potent vasodilators.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

LTB4 receptor

Inhibitors & Agonists